Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04967508
Recruitment Status : Active, not recruiting
First Posted : July 19, 2021
Last Update Posted : April 15, 2022
Information provided by (Responsible Party):
Samsung Bioepis Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : February 24, 2022
Estimated Study Completion Date : December 2022